During the last session, Metagenomi Inc (NASDAQ:MGX)’s traded shares were 0.6 million, with the beta value of the company hitting -0.89. At the end of the trading day, the stock’s price was $1.48, reflecting an intraday loss of -3.90% or -$0.06. The 52-week high for the MGX share is $11.13, that puts it down -652.03 from that peak though still a striking -3.38% loss since the share price plummeted to a 52-week low of $1.53. The company’s market capitalization is $55.33M, and the average intraday trading volume over the past 10 days was 0.47 million shares, and the average trade volume was 939.40K shares over the past three months.
Metagenomi Inc (MGX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.40. MGX has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.51.
Metagenomi Inc (NASDAQ:MGX) trade information
Metagenomi Inc (MGX) registered a -3.90% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.90% in intraday trading to $1.48, hitting a weekly high. The stock’s 5-day price performance is -9.76%, and it has moved by -28.50% in 30 days. Based on these gigs, the overall price performance for the year is -86.93%. The short interest in Metagenomi Inc (NASDAQ:MGX) is 2.64 million shares and it means that shorts have 6.21 day(s) to cover.
The consensus price target of analysts on Wall Street is $14.5, which implies an increase of 89.79% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $22 respectively. As a result, MGX is trading at a discount of -1386.49% off the target high and -372.97% off the low.
Metagenomi Inc (MGX) estimates and forecasts
In the rating firms’ projections, revenue will decrease -38.98% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 7.96M as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 8.52M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 11.16M and 20.01M respectively. In this case, analysts expect current quarter sales to shrink by -28.67% and then drop by -57.42% in the coming quarter.
While earnings are projected to return -3.19% in 2025, the next five years will return -16.92% per annum.
MGX Dividends
Metagenomi Inc is due to release its next quarterly earnings on 2025-Mar-16. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Metagenomi Inc (NASDAQ:MGX)’s Major holders
Metagenomi Inc insiders own 28.83% of total outstanding shares while institutional holders control 28.78%, with the float percentage being 40.44%. NOVO HOLDINGS A/S is the largest shareholder of the company, while 100.0 institutions own stock in it. As of 2024-06-30, the company held over 1.8 million shares (or 4.9146% of all shares), a total value of $7.34 million in shares.
The next largest institutional holding, with 1.48 million shares, is of RA CAPITAL MANAGEMENT, L.P.’s that is approximately 4.0348% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $6.03 million.
Also, the Mutual Funds coming in first place with the largest holdings of Metagenomi Inc (MGX) shares are iShares Trust-iShares Russell 2000 ETF and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . Data provided on Feb 28, 2025 indicates that iShares Trust-iShares Russell 2000 ETF owns about 673.14 shares. This amounts to just over 1.80 percent of the company’s overall shares, with a $1.0 million market value. The same data shows that the other fund manager holds slightly less at 484.25, or about 1.30% of the stock, which is worth about $0.72 million.
